Trial Profile
Predictors of cardiovascular risks during Proteasome Inhibitor Therapy (Carfilzomib or Bortezomib) in patients with Relapsed-refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 May 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 07 May 2018 New trial record
- 12 Mar 2018 Results presented at the 67th Annual Scientific Session of the American College of Cardiology